Flindersine

Flindersine

SCHEMBL3125149

CC1(C)C=Cc2c(c3ccccc3[nH]c2=O)O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 1.00
▸ KDM4E B2RXH2 4/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ LMNA P02545 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ HPGD P15428 2/20 0.64
▸ CYP2C19 P33261 2/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ HTT P42858 1/20 0.64
▸ MAPT P10636 2/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ POLB P06746 1/20 0.56
▸ XBP1 P17861 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ CYP1A2 P05177 2/20 0.42
▸ PARP1 P09874 2/20 0.42
▸ TNKS O95271 1/20 0.42
▸ GPR3 P46089 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5902327 0.80 HSD17B10 (0.67) HSD17B10KDM4EALDH1A1MEN1LMNA
Haplamine SCHEMBL257952 0.79 ALDH1A1 (1.00) HSD17B10KDM4EALDH1A1MEN1LMNA
Haplamine SCHEMBL30203195 0.79 ALDH1A1 (1.00) HSD17B10KDM4EALDH1A1MEN1LMNA
SCHEMBL29035311 0.76 KMT2A (0.66) HSD17B10KDM4EALDH1A1MEN1LMNA
SCHEMBL30366382 0.76 KMT2A (0.66) HSD17B10KDM4EALDH1A1MEN1LMNA
Grinimibine SCHEMBL4132680 0.72 MAPT (1.00) HSD17B10KDM4EALDH1A1MEN1LMNA
SCHEMBL6272145 0.72 HSD17B10 (0.56) HSD17B10KDM4EALDH1A1MEN1LMNA
SCHEMBL28935130 0.67 KDM4E (0.57) HSD17B10KDM4EALDH1A1MEN1LMNA
SCHEMBL9626803 0.65 HSD17B10 (0.48) HSD17B10KDM4EALDH1A1MEN1LMNA
Flindersine SCHEMBL31655421 0.65 HSD17B10 (0.48) HSD17B10KDM4EALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103435584-A Preparation method of collinin NANJING TONGZE AGRICULTURE SCIENCE & TECHNOLOGY CO LTD 2013-12-11 — — CN claimed
US-10195216-B1 Antimicrobial activity and oil compositions of Costus speciosus (KOEN) KING ABDULAZIZ UNIVERSITY (SA) 2019-02-05 — — US disclosed
CN-104428036-A Polypeptides and their use NOVABIOTICS LTD 2015-03-18 — — CN disclosed
CN-103435584-A Preparation method of collinin NANJING TONGZE AGRICULTURE SCIENCE & TECHNOLOGY CO LTD 2013-12-11 — — CN disclosed
US-20100009927-A1 Anti-Inflammatory and Anti-Allergy Extracts from Nettle HERBALSCIENCE GROUP LLC (US) 2010-01-14 — — US disclosed
EP-0872903-B1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder SHINETSU CHEMICAL CO (JP) 2001-10-04 — — EP disclosed
US-6277519-B1 QUENCHING AN ALLOY MELT; COMMINUTION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2001-08-21 — — US disclosed
EP-0843371-B1 Hydrogen storage alloy powder and an electrode comprising the same SHINETSU CHEMICAL CO (JP) 2000-10-18 — — EP disclosed
US-6096144-A TREATING WITH ACIDIC OR ALKALINE SOLUTION OF CONJUGATED UNSATURATED COMPOUND WITH AT LEAST 5 BONDS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2000-08-01 — — US disclosed
US-5968225-A POWDER HAVING METALLIC NICKEL PRESENT ON OR IN SURFACE IN AN AMOUNT TO IMPART FAVORABLE MAGNETIZATION INTENSITY; BATTERIES SHIN-ETSU CHEMICAL CO., LTD. (JP) 1999-10-19 — — US disclosed
US-5858571-A TREATING A PULVERIZED HYDROGEN ABSORBING ALLOY WITH A SOLUTION COMPRISING A CONJUGATED UNSATURATED COMPOUND SHIN-ETSU CHEMICAL CO., LTD. (JP) 1999-01-12 — — US disclosed
EP-0872903-A1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder Shin-Etsu Chemical Co., Ltd. (JP) 1998-10-21 — — EP disclosed
EP-0843371-A1 Hydrogen storage alloy powder and an electrode comprising the same Shin-Etsu Chemical Co., Ltd. (JP) 1998-05-20 — — EP disclosed
US-5070088-A Pyranyl quinoline calcium channel blockers E. R. SQUIBB & SONS, INC. (US) 1991-12-03 — — US disclosed
EP-0172427-B1 PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER Shin-Etsu Chemical Co., Ltd. (JP) 1989-07-05 — — EP disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 — — US disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 — — US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10195216-B1 Antimicrobial activity and oil compositions of Costus speciosus (KOEN) CUTA, PTGES, FASN HSD17B10 594/4885KDM4E 1811/4885ALDH1A1 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback